View ValuationEndonovo Therapeutics 将来の成長Future 基準チェック /06現在、 Endonovo Therapeuticsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長25.2%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Nov 17Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 11/15/2023, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Oct 13Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA ApprovalEndonovo Therapeutics, Inc. announced the full regulatory approval of its product, SofPulse® by the Taiwan Food and Drug Administration (TFDA), the regulatory division of the Ministry of Health and Welfare (MOHW). The approval is a significant accomplishment in introducing innovative Pulsed Electro Magnetic Field (PEMF) technology into the Taiwanese surgical market through Endonovo's valued distribution partner, EverMed Medical Enterprises Co. The SofPulse® TFDA approval marks the initial phase of Endonovo's expansion, through EverMed, into the largely untapped PEMF and surgical sectors in Taiwan. Initial sales efforts will focus on introducing SofPulse® into multiple Taiwanese hospital surgical markets. EverMed will target four surgical specialties -- including cardiovascular surgery, orthopedic surgery, spinal surgery and plastic surgery -- representing hundreds of thousands of surgical cases. SofPulse® Commercialization in Taiwan: EverMed and Endonovo’s commercialization of SofPulse® in Taiwan commences with product registration with the NHI. This will be followed by an extensive sales and marketing campaign to introduce surgeons and patients to the benefits of PEMF therapy. Sales and marketing strategies include leveraging existing connections with MD’s, surgeons, hospitals and medical facilities to promote the expansion of surgical applications across Taiwan's three regions. As healthcare professionals and patients experience the tangible benefits of PEMF technology in post-operative care, SofPulse® is poised for success and wide acceptance throughout the Taiwanese surgical market. Taiwan FDA Process and International Expansion: The TFDA is the regulatory arm of Taiwan’s MOHW and is considered the driving force behind healthcare improvement in Taiwan. MOHW's focus is on promoting the health and well-being of all citizens in Taiwan by improving healthcare quality, advancing technological development, ensuring quality, efficiency, resource allocation contributing to international affairs. SofPulse® TFDA approval helps to validate Endonovo’s innovative approach to pain relief and non-opioid alternatives that has garnered widespread attention in the ever-growing global medical markets.お知らせ • Aug 17Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 08/15/2023, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 17Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 05/16/2023, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Dec 01Endonovo Therapeutics, Inc. Appoints Ira Weisberg President to Guide Global Medical ExpansionEndonovo Therapeutics, Inc. appointed Ira Weisberg as President and Chief Commercial Officer of its Medical Division. Weisberg has more than four decades of experience in healthcare and pharmaceutical management, business development, finance, sales and marketing. Weisberg’s past work experience includes positions as President and CEO of Amherst Pharmaceuticals, Senior VP and Corporate Development Officer at Neurotrope Bioscience. Other executive medical administrative experience include executive positions at ALPHAVAX, INC., LIFECYCLE PHARMA, CHUGAI PHARMA USA, HAEMACURE CORPORATION and AVENTIS BEHRING.お知らせ • Nov 15Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 11/14/2022, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Sep 29Endonovo Therapeutics, Inc. (OTCPK:ENDV) entered into an Asset Purchase Agreement to acquire Substantially all of the assets and assume certain liabilities of Western Star.Endonovo Therapeutics, Inc. (OTCPK:ENDV) entered into an Asset Purchase Agreement to acquire Substantially all of the assets and assume certain liabilities of Western Star Concrete, LLC from for $25.2 million on September 26, 2022. The deal is conditioned on Employment Agreements signed by Endonovo Therapeutics, The transaction is subject to Due diligence, and audit of Western Star’s financial statements for the years ended December 31, 2021 and December 31. The closing is anticipated to be held on or about December 15, 2022. Jack B. Eggleston of Eggleston King Davis, LLP acted as legal advisor to Endonovo Therapeutics.お知らせ • Aug 16Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 08/15/2022, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jul 29Endonovo Therapeutics Releases Comparative Analysis DemonstratingEndonovo Therapeutics, Inc. released superior comparative results for its SofPulse® medical device for post-operative pain relief compared with Bioelectronics Corporation’s RecoveryRx®. The medical treatment comparisons were clinically evaluated based on three clinical trials for RecoveryRx® and five published studies for SofPulse®. Product and technical characteristics comparisons for both devices were included in FDA-clearance material for both company’s Pulsed Electric Magnetic Frequency (PEMF) products, which are designed to alleviate post-operative reduction of pain and edema (swelling). Comparison of SofPulse® to RecoveryRx® in technical characteristics demonstrated superiority of the design, efficacy and health benefits of the Endonovo SofPulse® medical device.お知らせ • May 17Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 05/16/2022, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 16Endonovo Therapeutics, Inc. Auditor Raises 'Going Concern' DoubtEndonovo Therapeutics, Inc. filed its 10-K on Apr 14, 2022 for the period ending Dec 31, 2021. In this report its auditor, Rose, Snyder & Jacobs, gave an unqualified opinion expressing doubt that the company can continue as a going concern.お知らせ • Apr 01Endonovo Therapeutics, Inc. announced delayed annual 10-K filingOn 03/31/2022, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Mar 03Endonovo Therapeutics Inc. Appoints Garry Michael Kann as Head of Corporate DevelopmentEndonovo Therapeutics Inc. announced that it has appointed Garry Michael Kann as Head of Corporate Development to design, lead and execute its new corporate “build up strategy” of identifying and acquiring complementary specialty service providers in the construction industry. Mr. Kann will be responsible for management and oversight of creation and ongoing operation of all corporate development activities including oversight of potential acquisitions (Targets) identification activities, discussions regarding structuring of Transactions for Endonovo and management and oversite of Endonovo Merger and Acquisition staff. By Endonovo, establishing a Mergers and Acquisition division run by Mr. Kann, Endonovo will become a diversified holding company.お知らせ • Aug 17Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 08/16/2021, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 18Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 05/17/2021, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 02Endonovo Therapeutics, Inc. announced delayed annual 10-K filingOn 03/31/2021, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 18Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 11/16/2020, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Oct 10Endonovo Therapeutics’ Offers FDA Cleared Solution to Opioid Epidemic Which Has Significantly Increased During the COVID PandemicEndonovo Therapeutics, Inc. announced a new marketing and public awareness campaign around their FDA Cleared SofPulse® that has been proven to help the in the response to the opioid epidemic during the COVID pandemic. SofPulse® device is FDA Cleared for reduction of pain and edema post-operatively. It offers a non-opioid, non-invasive, non-pharmaceutical opioid mitigation treatment and it has no known side effects based upon over 20,000+ surgical uses since its introduction to post-surgical pain management. Management believes that SofPulse® is a viable solution to manage pain and edema for all in-patient hospital surgeries. However, the true value of adopting this preventative approach to the opioid epidemic is in the lives saved.お知らせ • Aug 12Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 08/11/2020, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Endonovo Therapeutics は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:ENDV - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/20230-4-1-1N/A6/30/20230-4-1-1N/A3/31/20230-9-1-1N/A12/31/20220-18-1-1N/A9/30/20220-3-1-1N/A6/30/20220-4-1-1N/A3/31/20220-3-1-1N/A12/31/20210-3-1-1N/A9/30/20210-8-1-1N/A6/30/20210-7-1-1N/A3/31/20210-7-1-1N/A12/31/202000-1-1N/A9/30/20200-4-1-1N/A6/30/20200-4-2-2N/A3/31/20200-11-2-2N/A12/31/20190-17-3-3N/A9/30/20190-10-3-3N/A6/30/20190-15-3-3N/A3/31/20190-8-3-3N/A12/31/20180-6-3-3N/A9/30/20180-6-6-3N/A6/30/20180-7-6-3N/A3/31/20180-4-6-3N/A12/31/2017N/A-11-6-3N/A9/30/2017N/A-13-3-3N/A6/30/2017N/A-9N/A-3N/A3/31/2017N/A-12N/A-2N/A12/31/2016N/A-5N/A-2N/A9/30/2016N/A-9N/A-2N/A6/30/20160-8N/A-2N/A3/31/20160-7N/A-1N/A12/31/20150-7N/A-1N/A9/30/20150-2N/A-1N/A6/30/20150-1N/A-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ENDVの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ENDVの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ENDVの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ENDVの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ENDVの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ENDVの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 14:55終値2026/05/11 00:00収益2023/09/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Endonovo Therapeutics, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Nov 17Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 11/15/2023, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Oct 13Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA ApprovalEndonovo Therapeutics, Inc. announced the full regulatory approval of its product, SofPulse® by the Taiwan Food and Drug Administration (TFDA), the regulatory division of the Ministry of Health and Welfare (MOHW). The approval is a significant accomplishment in introducing innovative Pulsed Electro Magnetic Field (PEMF) technology into the Taiwanese surgical market through Endonovo's valued distribution partner, EverMed Medical Enterprises Co. The SofPulse® TFDA approval marks the initial phase of Endonovo's expansion, through EverMed, into the largely untapped PEMF and surgical sectors in Taiwan. Initial sales efforts will focus on introducing SofPulse® into multiple Taiwanese hospital surgical markets. EverMed will target four surgical specialties -- including cardiovascular surgery, orthopedic surgery, spinal surgery and plastic surgery -- representing hundreds of thousands of surgical cases. SofPulse® Commercialization in Taiwan: EverMed and Endonovo’s commercialization of SofPulse® in Taiwan commences with product registration with the NHI. This will be followed by an extensive sales and marketing campaign to introduce surgeons and patients to the benefits of PEMF therapy. Sales and marketing strategies include leveraging existing connections with MD’s, surgeons, hospitals and medical facilities to promote the expansion of surgical applications across Taiwan's three regions. As healthcare professionals and patients experience the tangible benefits of PEMF technology in post-operative care, SofPulse® is poised for success and wide acceptance throughout the Taiwanese surgical market. Taiwan FDA Process and International Expansion: The TFDA is the regulatory arm of Taiwan’s MOHW and is considered the driving force behind healthcare improvement in Taiwan. MOHW's focus is on promoting the health and well-being of all citizens in Taiwan by improving healthcare quality, advancing technological development, ensuring quality, efficiency, resource allocation contributing to international affairs. SofPulse® TFDA approval helps to validate Endonovo’s innovative approach to pain relief and non-opioid alternatives that has garnered widespread attention in the ever-growing global medical markets.
お知らせ • Aug 17Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 08/15/2023, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 17Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 05/16/2023, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Dec 01Endonovo Therapeutics, Inc. Appoints Ira Weisberg President to Guide Global Medical ExpansionEndonovo Therapeutics, Inc. appointed Ira Weisberg as President and Chief Commercial Officer of its Medical Division. Weisberg has more than four decades of experience in healthcare and pharmaceutical management, business development, finance, sales and marketing. Weisberg’s past work experience includes positions as President and CEO of Amherst Pharmaceuticals, Senior VP and Corporate Development Officer at Neurotrope Bioscience. Other executive medical administrative experience include executive positions at ALPHAVAX, INC., LIFECYCLE PHARMA, CHUGAI PHARMA USA, HAEMACURE CORPORATION and AVENTIS BEHRING.
お知らせ • Nov 15Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 11/14/2022, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Sep 29Endonovo Therapeutics, Inc. (OTCPK:ENDV) entered into an Asset Purchase Agreement to acquire Substantially all of the assets and assume certain liabilities of Western Star.Endonovo Therapeutics, Inc. (OTCPK:ENDV) entered into an Asset Purchase Agreement to acquire Substantially all of the assets and assume certain liabilities of Western Star Concrete, LLC from for $25.2 million on September 26, 2022. The deal is conditioned on Employment Agreements signed by Endonovo Therapeutics, The transaction is subject to Due diligence, and audit of Western Star’s financial statements for the years ended December 31, 2021 and December 31. The closing is anticipated to be held on or about December 15, 2022. Jack B. Eggleston of Eggleston King Davis, LLP acted as legal advisor to Endonovo Therapeutics.
お知らせ • Aug 16Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 08/15/2022, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jul 29Endonovo Therapeutics Releases Comparative Analysis DemonstratingEndonovo Therapeutics, Inc. released superior comparative results for its SofPulse® medical device for post-operative pain relief compared with Bioelectronics Corporation’s RecoveryRx®. The medical treatment comparisons were clinically evaluated based on three clinical trials for RecoveryRx® and five published studies for SofPulse®. Product and technical characteristics comparisons for both devices were included in FDA-clearance material for both company’s Pulsed Electric Magnetic Frequency (PEMF) products, which are designed to alleviate post-operative reduction of pain and edema (swelling). Comparison of SofPulse® to RecoveryRx® in technical characteristics demonstrated superiority of the design, efficacy and health benefits of the Endonovo SofPulse® medical device.
お知らせ • May 17Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 05/16/2022, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 16Endonovo Therapeutics, Inc. Auditor Raises 'Going Concern' DoubtEndonovo Therapeutics, Inc. filed its 10-K on Apr 14, 2022 for the period ending Dec 31, 2021. In this report its auditor, Rose, Snyder & Jacobs, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
お知らせ • Apr 01Endonovo Therapeutics, Inc. announced delayed annual 10-K filingOn 03/31/2022, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Mar 03Endonovo Therapeutics Inc. Appoints Garry Michael Kann as Head of Corporate DevelopmentEndonovo Therapeutics Inc. announced that it has appointed Garry Michael Kann as Head of Corporate Development to design, lead and execute its new corporate “build up strategy” of identifying and acquiring complementary specialty service providers in the construction industry. Mr. Kann will be responsible for management and oversight of creation and ongoing operation of all corporate development activities including oversight of potential acquisitions (Targets) identification activities, discussions regarding structuring of Transactions for Endonovo and management and oversite of Endonovo Merger and Acquisition staff. By Endonovo, establishing a Mergers and Acquisition division run by Mr. Kann, Endonovo will become a diversified holding company.
お知らせ • Aug 17Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 08/16/2021, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 18Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 05/17/2021, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 02Endonovo Therapeutics, Inc. announced delayed annual 10-K filingOn 03/31/2021, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 18Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 11/16/2020, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Oct 10Endonovo Therapeutics’ Offers FDA Cleared Solution to Opioid Epidemic Which Has Significantly Increased During the COVID PandemicEndonovo Therapeutics, Inc. announced a new marketing and public awareness campaign around their FDA Cleared SofPulse® that has been proven to help the in the response to the opioid epidemic during the COVID pandemic. SofPulse® device is FDA Cleared for reduction of pain and edema post-operatively. It offers a non-opioid, non-invasive, non-pharmaceutical opioid mitigation treatment and it has no known side effects based upon over 20,000+ surgical uses since its introduction to post-surgical pain management. Management believes that SofPulse® is a viable solution to manage pain and edema for all in-patient hospital surgeries. However, the true value of adopting this preventative approach to the opioid epidemic is in the lives saved.
お知らせ • Aug 12Endonovo Therapeutics, Inc. announced delayed 10-Q filingOn 08/11/2020, Endonovo Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.